A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis

Haematologica. 2014 Jan;99(1):e5-7. doi: 10.3324/haematol.2013.096669.
No abstract available

Keywords: clinical response; monotherapy; post-polycythemia vera; primary myelofibrosis; vorinostat.

Publication types

  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Humans
  • Hydroxamic Acids / therapeutic use*
  • Polycythemia Vera / complications*
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / drug therapy*
  • Treatment Outcome
  • Vorinostat

Substances

  • Hydroxamic Acids
  • Vorinostat